Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3

Positive top-line Phase III results have been released on the use of Sanofi/Regeneron's Dupixent in adolescents with moderate-to-severe atopic dermatitis, adding to the evidence supporting its use in adults.

Teenagers
• Source: Shutterstock

A skin condition may arguably have a greater impact on the well-being of adolescents than on adults, underlining the importance of Sanofi and Regeneron Pharmaceuticals Inc. reporting on May 16 positive Phase III results with Dupixent (dupilumab) in the younger age group of patients with inadequately controlled moderate-to-severe atopic dermatitis.

The interleukin4/IL-13 inhibitor, Dupixent, is the first and only biologic to show positive results as monotherapy in adolescents aged 12...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category